Sex stratified analysis of patients with resistant hypertension from the Global SYMPLICITY Registry of renal denervation
Our aim was a sex-specific analysis to characterize the phenotype for women with resistant hypertension (rHTN), an understudied population, referred for renal denervation (RDN) from the Global SYMPLICITY Registry DEFINE (N = 3332 patients). For this analysis, 2502 patients with uncontrolled hypertension (office systolic blood pressure (SBP) ≥140 mmHg, ≥3 antihypertensive drugs) were referred for RDN. Age at baseline was 18-88 years for men and 21-89 years for women. We used propensity score matching to account for demographic differences at baseline identified by multivariate regression analysis. Changes in BP, outcomes (all-cause death, cardiac death, stroke, myocardial infarction), and quality of life (QoL) after 36 months were assessed. Women had fewer comorbidities at baseline but had higher BP and worse QoL, anxiety, and depression compared to men. After propensity matching to minimize bias, BP changes were comparable by sex, and BP was significantly reduced from baseline following RDN. Women ≥55 years of age with resistant hypertension had a greater reduction in BP compared with women <55 years. At 36 months after RDN, there was a significant 12% reduction in anxiety/depression compared to baseline for women with resistant hypertension. When baseline office SBP was in the highest tertile (>178 mmHg), cardiac death was more prevalent in women (6.1%) than men (1.7%). Our sex-stratified analysis of the global registry allowed a longitudinal assessment, providing important insights into the phenotype of resistant hypertension in women. We identified sex-specific differences that highlight the need for early detection and management of hypertension in women.
Authors
- Joachim Weil (ORCID: https://orcid.org/0000-0002-7519-6912)
- Douglas A. Hettrick (ORCID: https://orcid.org/0000-0002-8957-7740)
- Felix Mahfoud (ORCID: https://orcid.org/0000-0002-4425-549X)
- Luís M. Ruilope (ORCID: https://orcid.org/0000-0001-6278-7951)
- Laura Nickel
- Markus Peter Schlaich (ORCID: https://orcid.org/0000-0002-1765-0195)
- Roland Erich Schmieder (ORCID: https://orcid.org/0000-0003-2356-5883)
- Martin Fahy
- Anastasia S. Mihailidou (ORCID: https://orcid.org/0000-0001-6435-0411)
- Krzysztof Narkiewicz (ORCID: https://orcid.org/0000-0001-5949-5018)
- G. Mancia
- M. Böhm
Institutions
- New South Wales Department of Health (AU)
- Royal Perth Hospital (AU)
- Royal North Shore Hospital (AU)
- University Hospital of Basel (CH)
- Universitätsklinikum Erlangen (DE)
- Medtronic (United States) (US)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Northern Sydney Local Health District (AU)
- University of Milano-Bicocca (IT)
- Gdańsk Medical University (PL)
- Universidad Europea de Madrid (ES)
- Saarland University (DE)
Publication Details
- Journal
- Hypertension Research
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1038/s41440-025-02446-y
- Citations
- 1
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Cytokinetics
- ReCor Medical
- Deutsche Forschungsgemeinschaft
- Novo Nordisk
- Universität des Saarlandes
- Deutsche Herzstiftung
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- Servier
- Idorsia Pharmaceuticals